Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Evaluation of MAF-1217 in Patients With DED

12. juli 2019 opdateret af: VISUfarma SpA

Evaluation of the Performance of the Tear Substitute MAF-1217 in Patients With Evaporative DED

This is a pre-market, multicentre, double-blind, randomized, crossover, non-inferiority study comparing the efficacy of MAF-1217 and Cationorm® in adult patients with evaporative DED.

The study population will be divided in 4 different subgroups, according to the different types of evaporative DED:

  1. Group A: high evaporative levels
  2. Group B: females in menopause, whether using hormonal integration or not
  3. Group C: presence of active obstructive Meibomian gland disease
  4. Group D: glaucomatous patients

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Patients will be enrolled after having signed the informed consent form prior any other study procedure and after inclusion/exclusion criteria check.

Each patient will be planned to perform 6 study visits and at each visit all necessary study procedures will be performed according to the clinical investigation plan requirements (see flow-chart).

The study visits will be performed at: screening, baseline, week 2, week 6, week 8, week 12.

Patients will be enrolled at screening visit and at baseline, after the wash-out period of 1 week, then will be randomized to receive MAF-1217 or Cationorm® for the following 6 weeks.

After this time lapse, patients will be switched to the opposite therapy for 6 additional weeks.

The entire study population will be asked for a TID posology, and will be divided in 4 different subgroups, according to the different types of evaporative DED.

Certain test will be performed only in some patients:

Osmolimetry and tear sampling in 20 patients(10/site) chosen random from groups B, C and D; Ferning test only in group D; tear film collection and cytokine expression only in 20 patients form site nr. 2.

Patients will be allowed to carry on any systemic or local medications, apart lubricating eyedrops, which have to be stopped the day before baseline visit.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

72

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Milan, Italien, 20121
        • Ospedale San Paolo, ASST Santi Paolo e Carlo
      • Milan, Italien, 20157
        • ASST Fatebenefratelli Sacco P.O.L. Sacco

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. At least 18 years old (adult patients), male and female
  2. Schirmer I test > 10 mm at 5'
  3. (Group A): high evaporative levels
  4. (Group B): females in menopause, both using hormonal integration or not
  5. (Group C): presence of active obstructive Meibomian gland disease, defined as at least one of the following:

    • Meibomian orifice plugging
    • eyelid margin foaminess
    • changes in orifice position with respect to the mucocutaneous junction
    • abnormal Meibomian gland secretions (opaque and viscous-like form that is difficult to express)
  6. (Group D): glaucomatous patients receiving one or more BAK preserved treatments for at least 2 years, showing an abnormal Ferning test (Types 3 or 4 according to Rolando)
  7. all: wishing to participate in the study and able to sign the ICF

Inclusion criteria to be checked at baseline:

  1. BUT < 7"
  2. Mild to severe DED according to OSDI chart

Exclusion Criteria:

  1. Neuropathic causes of dry eye (diabetes, long-standing contact lens wearing, previous ocular herpes infections)
  2. Coexisting corneal diseases
  3. Autoimmune diseases
  4. Past or active cicatricial conjunctivitis
  5. Past ocular surface burns
  6. Keratinization of the eyelid margin
  7. Sjogren syndrome
  8. History of corneal trauma
  9. Pregnant and lactating women
  10. Younger than 18 years old patients
  11. Use of contact lenses
  12. inability to self administer study medications
  13. (GROUPS B, D) Presence of active obstructive Meibomian gland disease
  14. (GROUP C) Presence of cicatricial Meibomian gland disease
  15. known allergic sensitivity to any of the devices ingredients or any other known allergy
  16. participation in a clinical trial during the 3 months prior to the beginning of the study

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: MAF1217/Cationorm
The study population will have to self-administer the study treatment in a TID posology.
The study population will have to self-administer the study treatment in a TID posology.
Eksperimentel: Cationorm/MAF1217
The study population will have to self-administer the study treatment in a TID posology.
The study population will have to self-administer the study treatment in a TID posology.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Break-up time (BUT) differences
Tidsramme: measured at week 2, 6, 8 and 12 weeks treatment versus baseline
Changes in break-up time (BUT) versus baseline
measured at week 2, 6, 8 and 12 weeks treatment versus baseline

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
ocular surface staining (corneal and conjunctival)
Tidsramme: measured at week 2, 6, 8 and 12 weeks treatment versus baseline
Cross-over analysis for the differences versus baseline between the two groups on changes in ocular surface staining (corneal and conjunctival)
measured at week 2, 6, 8 and 12 weeks treatment versus baseline
Schirmer I test (ST) (without anesthesia)
Tidsramme: measured at week 2, 6, 8 and 12 weeks treatment versus baseline
Cross-over analysis for the differences versus baseline between the two groups on changes in Schirmer I test (ST) (without anesthesia)
measured at week 2, 6, 8 and 12 weeks treatment versus baseline
number of blinking per minute
Tidsramme: measured at week 2, 6, 8 and 12 weeks treatment versus baseline
Cross-over analysis for the differences versus baseline between the two groups on changes in number of blinking per minute
measured at week 2, 6, 8 and 12 weeks treatment versus baseline
Ferning test (Group D)
Tidsramme: measured at week 2, 6, 8 and 12 weeks treatment versus baseline
Cross-over analysis for the differences versus baseline between the two groups on changes in Ferning test (Group D)
measured at week 2, 6, 8 and 12 weeks treatment versus baseline
osmolarity
Tidsramme: measured at week 2, 6, 8 and 12 weeks treatment versus baseline
Cross-over analysis for the differences versus baseline between the two groups on changes in osmolarity
measured at week 2, 6, 8 and 12 weeks treatment versus baseline
patient satisfaction (10 points VAS scale)
Tidsramme: measured at week 2, 6, 8 and 12 weeks treatment versus baseline

Cross-over analysis for the differences versus baseline between the two groups on changes in patient satisfaction (10 points VAS scale).

(VAS: scale where patient has to specify level of satisfaction by indicating a position along a continuous line between two end-points (0 - 10). 0 indicates no satisfaction while 10 represents the highest level).

measured at week 2, 6, 8 and 12 weeks treatment versus baseline
OSDI
Tidsramme: measured at week 2, 6, 8 and 12 weeks treatment
Changes in questionnaire scores (OSDI - Ocular Surface Disease Index). The overall Ocular Surface Disease score defined the ocular surface as normal (0-12 points) or as having mild (13-22 points), moderate (23-32 points), or severe (33-100 points) disease.
measured at week 2, 6, 8 and 12 weeks treatment

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

27. november 2018

Primær færdiggørelse (Faktiske)

19. juni 2019

Studieafslutning (Faktiske)

19. juni 2019

Datoer for studieregistrering

Først indsendt

31. januar 2019

Først indsendt, der opfyldte QC-kriterier

4. februar 2019

Først opslået (Faktiske)

7. februar 2019

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

15. juli 2019

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

12. juli 2019

Sidst verificeret

1. juli 2019

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • VF-OS-001/2018

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

Uafklaret

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .